A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines

Inclusion criteria

• Participants (male or female) must be ≥18 years old, at the time of signing the informed consent.
• At screening and baseline, participants must have moderate to severe glabellar lines at maximum frown (grade 2 or 3 on the relevant 4-point scale), as assessed by both the investigator and the participant.
• Male or female (inclusive of all gender identities) participants are eligible to participate if they agree to practice adequate contraceptive methods during the study period and for at least 3 months after the study drug administration. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Participant must provide signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Participant must have the time and ability to complete the study and comply with instructions, at the discretion of the investigator.

Exclusion criteria

• Known allergy or hypersensitivity to any components of the investigational product or any botulinum toxin serotype.
• A history or presence of ptosis, significant facial asymmetry, excessive dermatochalasis at screening or baseline.
• A history or presence of facial nerve palsy at screening or baseline.
• A positive HIV, hepatitis B or hepatitis C test at screening.
• History or presence of other concomitant diseases which are assessed by the investigator to be unsuitable for participation in this clinical research.
• History of drug or alcohol abuse.
• History or presence of epilepsy.
• Have a serious mental disorder that, in the Investigator's opinion, may affect participant compliance with the study.
• Female who is pregnant or breast feeding.
• Abnormal laboratory tests that, in the Investigator's assessment, are not appropriate for participation in this study.
• Participation in an investigational device or drug study within 30 days or 5 half-lives (whichever is longer) prior to screening.
• Study center personnel, close relatives of the study center personnel, employees or close relatives of employees at the sponsor company.